Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Ikkou Group CoTSE:3353 -0.88%63 Return-on-Tangible-Equity is 8.57% as of Feb. 2026, which is 7% below its 10-year median of 9.26. GuruFocus rates TSE:3353 with a GF Score™ of 63/100 and a GF Value™ of 円3,534.01 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 552 Conglomerates companies, Medical Ikkou Group Co ranks better than 57.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medical Ikkou Group Co's annualized net income for the quarter that ended in Feb. 2026 was 円1,216 Mil. Medical Ikkou Group Co's average shareholder tangible equity for the quarter that ended in Feb. 2026 was 円14,186 Mil. Therefore, Medical Ikkou Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 was 8.57%.
The historical rank and industry rank for Medical Ikkou Group Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3353'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.51 Med: 9.26 Max: 16.62
Current: 9.22
During the past 13 years, Medical Ikkou Group Co's highest Return-on-Tangible-Equity was 16.62%. The lowest was 7.51%. And the median was 9.26%.
TSE:3353's Return-on-Tangible-Equity is ranked better than 57.07% of 552
companies
in the Conglomerates industry
Industry Median: 7.465
vs TSE:3353: 9.22
Medical Ikkou Group Co (TSE:3353) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medical Ikkou Group Co Return-on-Tangible-Equity Related Terms
Medical Ikkou Group Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medical Ikkou Group Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Ikkou Group Co Return-on-Tangible-Equity Chart
TSE:3353 vs HON, MMM: Return-on-Tangible-Equity Comparison
For the Conglomerates subindustry, Medical Ikkou Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Ikkou Group Co Return-on-Tangible-Equity vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medical Ikkou Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Feb. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.57% mean?
Medical Ikkou Group Co (TSE:3353) has a Return-on-Tangible-Equity of 8.57% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medical Ikkou Group Co and its competitors. This is near median its historical median of 9.26. Over the past decade, Medical Ikkou Group Co's Return-on-Tangible-Equity has ranged from 7.51 to 16.62. According to the industry distribution chart, Medical Ikkou Group Co ranks #237 out of 552 companies in the Conglomerates industry, placing it in the top 42.9%.
Is Medical Ikkou Group Co's Return-on-Tangible-Equity too high?
Medical Ikkou Group Co's current Return-on-Tangible-Equity of 8.57% is near median its 10-year median of 9.26. Over the past 10 years, this metric has ranged from a low of 7.51 to a high of 16.62. The Conglomerates industry median Return-on-Tangible-Equity is 7.47. Medical Ikkou Group Co's value of 8.57% is 14.8% above this industry median. Based on the distribution chart, Medical Ikkou Group Co ranks #237 out of 552 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Medical Ikkou Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's Return-on-Tangible-Equity compare to HON and MMM?
According to the Conglomerates industry distribution chart, Medical Ikkou Group Co ranks #237 out of 552 companies for Return-on-Tangible-Equity. This puts Medical Ikkou Group Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.47. Medical Ikkou Group Co's value of 8.57% is 14.8% above this benchmark. Historically, Medical Ikkou Group Co's own Return-on-Tangible-Equity has ranged from 7.51 to 16.62 over the past decade. While the company's 10-year median is 9.26 vs. the industry median of 7.47, Medical Ikkou Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Conglomerates company?
The median Return-on-Tangible-Equity among Conglomerates companies is 7.47, based on 552 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Ikkou Group Co's current Return-on-Tangible-Equity of 8.57% is 14.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medical Ikkou Group Co and its competitors. For the Conglomerates industry, the median Return-on-Tangible-Equity is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Ikkou Group Co's current Return-on-Tangible-Equity is 8.57%, which is near median its own 10-year median of 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,534.01, compared to a current price of 円2,816.00 — trading 20.3% below its estimated fair value. The current Return-on-Tangible-Equity is 8.57%, which is near median its 10-year median of 9.26 and 14.8% above the Conglomerates industry median of 7.47. Medical Ikkou Group Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current Return-on-Tangible-Equity is 8.57% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued.
The current stock price of 円2,816.00 is trading 20.3% below its estimated GF Value™ of 円3,534.01.
GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.
Key valuation signals for TSE:3353:
Return-on-Tangible-Equity: 8.57% (near median its 10-year median of 9.26)
GF Value™: 円3,534.01 vs. price of 円2,816.00 (20.3% below fair value)
Industry Position: 14.8% above the Conglomerates median (#237 of 552)
No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
63GF Score
Get the complete analysis for TSE:3353
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3353 has been successfully added to your 
